Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1

Gene

Volumn 538, Issue 2, 2014, Pages 342-347

  Qin, Jun ^a   Luo, Meng ^a   Qian, Haixin ^b   Chen, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; HCC; MiR 182; TP53INP1

Indexed keywords

CHEMORESISTANCE; CISPLATIN; HCC; MIR-182; TP53INP1;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HEAT-SHOCK PROTEINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; MIDDLE AGED; RNA, NEOPLASM; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84893904578     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.12.043     Document Type: Article

References (29)

1. Bao B., Ali S., Kong D., et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
2. Chen C., Ridzon D.A., Broomer A.J., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33:e179.
3. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999, 340:745-750.
4. Esaki T., Nakano S., Masumoto N., Fujishima H., Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int. J. Cancer 1996, 65:479-484.
5. Geng W., Ng K.T., Sun C.K., et al. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One 2011, 6:e27362.
6. Gironella M., Seux M., Xie M.J., et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16170-16175.
7. Hershko T., Chaussepied M., Oren M., Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ. 2005, 12:377-383.
8. Husted S., Sokilde R., Rask L., et al. MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. Mol. Pharm. 2011, 8:2055-2062.
9. Hwang H.W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006, 94:776-780.
10. Jiang F., Liu T., He Y., et al. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 2011, 11:425.
11. Kerr S.H., Kerr D.J. Novel treatments for hepatocellular cancer. Cancer Lett. 2009, 286:114-120.
12. Kim N.Y., Sun J.M., Kim Y.J., et al. Cisplatin-based combination chemotherapy for advanced hepatocellular carcinoma: a single center experience before the sorafenib era. Cancer Res. Treat. 2010, 42:203-209.
13. Lei R., Tang J., Zhuang X., et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene 2013, 10.1038/onc.2013.65.
14. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 1999, 49:33-64. (31).
15. Robin T.P., Smith A., McKinsey E., Reaves L., Jedlicka P., Ford H.L. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol. Cancer Res. 2012, 10:1098-1108.
16. Saito Y., Suzuki H., Tsugawa H., et al. Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 2009, 28:2738-2744.
17. Tomasini R., Samir A.A., Carrier A., et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J. Biol. Chem. 2003, 278:37722-37729.
18. Tomasini R., Seux M., Nowak J., et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005, 24:8093-8104.
19. Tomimaru Y., Eguchi H., Nagano H., et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br. J. Cancer 2010, 103:1617-1626.
20. Wang F., Li X., Xie X., Zhao L., Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008, 582:1919-1927.
21. Wang J., Li J., Shen J., Wang C., Yang L., Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12:227.
22. Wang H., Tan G., Dong L., et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012, 7:e34210.
23. Wang Y.Q., Guo R.D., Guo R.M., Sheng W., Yin L.R. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J. Cell. Biochem. 2013, 114:1464-1473.
24. Xie Q., Chen X., Lu F., et al. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 2012, 118:2431-2442.
25. Xu N., Zhang J., Shen C., et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun. 2012, 423:826-831.
26. Xu N., Shen C., Luo Y., et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem. Biophys. Res. Commun. 2012, 425:468-472.
27. Yang A., Ma J., Wu M., et al. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk. Lymphoma 2012, 53:2465-2473.
28. Zhang Y., Wei W., Cheng N., et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.
29. Zhou M., Liu Z., Zhao Y., et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 2010, 285:21496-21507.